“…In the former, such as cerebellar medulloblastomas, retinoblastomas, central and peripheral (sympathoadrenal) neuroblastomas and pheochromocytomas, the expression of bIII-tubulin in tumor cells is constitutive, associated with morphological changes of neuronal differentiation, such as elaboration of neuritc cell processes (neuritogenesis) and decreased cell proliferation (Katsetos et al, 2003a,b,c). In contrast, the expression of bIII-tubulin in non-neuronal tumors, such as common epithelial tumors of the lung, including small cell-and non-small cell lung carcinomas (NSCLC) (Katsetos et al, 2000;Dumontet et al, 2005;Sève et al, 2005aSève et al, ,b, 2007a, in adenocarcinomas of the ovary (Ferrandina et al, 2006;Ohishi et al, 2007), breast (Bernard-Marty et al, 2002;Hasegawa et al, 2003;Paradiso et al, 2005;Tommasi et al, 2007), stomach (Urano et al, 2006) and prostate, as well as in gliomas of the CNS (Katsetos et al, 2001(Katsetos et al, , 2002(Katsetos et al, , 2003b(Katsetos et al, , 2007, is associated with a trend towards an higher histological grade of malignancy and poor prognosis.…”